Abstract:Lung cancer (LC) is the second most prevalent type of cancer and primary cause of mortality among both men and women, worldwide. The most commonly employed diagnostic modalities for LC include chest X-ray (CXR), magnetic-resonance-imaging (MRI), computed tomography (CT-scan), and fused-positron-emitting-tomography-CT (PET-CT). Owing to several limitations associated with the use of conventional diagnostic tools such as radiation burden to the patient, misleading diagnosis (“missed lung cancer”), false staging and low sensitivity and resolution, contemporary diagnostic regimen needed to be employed for screening of LC. In recent decades, nanotechnology-guided interventions have been transpired as emerging nanoimaging probes for detection of LC at advanced stages, while producing signal amplification, better resolution for surface and deep tissue imaging, and enhanced translocation and biodistribution of imaging probes within the cancerous tissues. Besides enormous potential of nanoimaging probes, nanotechnology-based advancements have also been evidenced for superior efficacy for treatment of LC and abolishing pulmonary metastasis (PM). The success of nanotherapeutics is due to their ability to maximise translocation and biodistribution of anti-neoplastic agents into the tumor tissues, improve pharmacokinetic profiles of anti-metastatic agents, optimise target-specific drug delivery, and control release kinetics of encapsulated moieties in target tissues. This review aims to overview and critically discuss the superiority of nanoimaging probes and nanotherapeutics over conventional regimen for early detection of LC and abolishing PM. Current challenges to clinical transition of nanoimaging probes and therapeutic viability of nanotherapeutics for treatment for LC and PM have also been pondered.

Research Progress of Nanomedicine for Lung Cancer

Nanomedicine in Lung Cancer: Current States of Overcoming Drug Resistance and Improving Cancer Immunotherapy

Nanotechnology: Breaking the Current Treatment Limits of Lung Cancer

Nanotechnology and Nanomedicine: A Promising Avenue for Lung Cancer Diagnosis and Therapy

Recent Progress of Lung Cancer Diagnosis Using Nanomaterials

Advances in Lung Cancer Treatment Using Nanomedicines

Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy

Current role of nanoparticles in the treatment of lung cancer

Nanomedicines Guided Nanoimaging Probes and Nanotherapeutics for Early Detection of Lung Cancer and Abolishing Pulmonary Metastasis: Critical Appraisal of Newer Developments and Challenges to Clinical Transition.

Moving beyond traditional therapies: the role of nanomedicines in lung cancer

Nanomedicines guided nanoimaging probes and nanotherapeutics for early detection of lung cancer and abolishing pulmonary metastasis: Critical appraisal of newer developments and challenges to clinical transition

Research Progress of Targeted Nanomaterials on Cancer Diagnose and Therapy

Nano-immunotherapy for Lung Cancer

Nanotechnology for the theranostic opportunity of breast cancer lung metastasis: recent advancements and future challenges

The Design and Application of Nanomaterials as Drug Carriers in Cancer Treatment

Recent Progress on Nanoparticle-Based Drug Delivery Systems for Cancer Therapy

Nanomedicine Combats Drug Resistance in Lung Cancer

Nanoparticle-based medicines in clinical cancer therapy

Nanoengineered Polymers and Other Organic Materials in Lung Cancer Treatment: Bridging the Gap Between Research and Clinical Applications

Formulations, Pharmacodynamic and Clinical Studies of Nanoparticles for Lung Cancer Therapy - an Overview

Current advance of nanotechnology in diagnosis and treatment for malignant tumors